Oppenheimer analyst Jay Olson maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) on November 11 and set a price target of $50.00. The company’s shares closed yesterday at $29.89.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
The local Athabaskan Indians reverently called the perpetually snow-covered mountain Denali, "The High One." But in 1896, when the region was still marked as "unexplored" on official maps ...
TAIPEI, Taiwan (BRAIN) — Giant Group's sales in the first nine months of its fiscal year were down 7.1% compared to the same period last year. The company said that while bike inventory levels ...
And so it begins again. November is upon us and as predictable as clockwork, the bike shops have launched their sales and the 2024 Black Friday bike deals have started flooding in. Here, in the ...
In the medical field, being fast, efficient, and correct can be the difference between life and death. This game-changing tool is helping cancer researchers and doctors save lives.